PHARMACEUTICAL FORMULATIONS OF HIF PROLYL HYDROXYLASE INHIBITOR

• Main Authors: SCOTT DAVID LEIGH, CLAUDIA WITSCHI, LEE ALLEN FLIPPIN, DAVID CONCA, LEE ROBERT WRIGHT
• Format: Patent
• Language: English; Japanese
• Published: 22.08.2019
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.SOLUTION: In one embodiment, the pharmaceutical formulation comprises less than about 0.2% w/w (based on the amount of an active pharmaceutical ingredient ("API")) of a photodegradation product of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid. In another embodiment, a photostabilizing agent blocks light in a wavelength range from about 200 to about 550 nm.SELECTED DRAWING: None 【課題】［（４−ヒドロキシ−１−メチル−７−フェノキシ−イソキノリン−３−カルボニル）−アミノ］−酢酸の医薬製剤と、その使用方法を提供すること。【解決手段】一実施形態では、医薬製剤は、［（４−ヒドロキシ−１−メチル−７−フェノキシ−イソキノリン−３−カルボニル）−アミノ］−酢酸の光分解生成物を約０．２％ｗ／ｗ未満（活性医薬成分（「ＡＰＩ」）の量に対して）含む。別の実施形態では、光安定化剤は、約２００から約５５０ｎｍの間の波長範囲の光を遮断する。【選択図】なし